BridgeMD
Add-on Clioquinol in drug-resistant epilepsy: an exploratory study
EU CTIS ID: 2024-511388-27-04
What this study is testing
To study whether add-on clioquinol decreases the seizure frequency and severity in patients with drug-resistant epilepsy.
- Therapeutic exploratory (Phase II)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Drug-resistant epilepsy: ≥ 4 seizures in the 2 week prospective period (baseline) before visit 2, not all (4) seizures observed in 1 of the 2 weeks. Baseline period can be extended with 1 or 2 weeks.
- Age ≥ 12 years and < 35 years at time of inclusion
- Drug-resistant epilepsy: before inclusion failure of at least 2 AEDs
- The patient is at the moment of inclusion on max 4 anti-epileptic drugs (VNS and ketogenic diet not included)
- Well defined epilepsy history with convulsive seizures (with observable and countable motor component)
You likely can't join if
- Presence of C609T NQO1 SNP after SNP analysis of NQO1 based on a blood sample during baseline visit (visit 1) by Genomics Core
- Asian etnicity
- Abnormal low blood level of vitamin B12 or Zn
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 0-17 years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.